These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22186318)

  • 21. Lysozyme in corneal ulcer.
    Mehra KS; Singh R; Bhatia RP; Sen PC; Singh H
    Ann Ophthalmol; 1975 Nov; 7(11):1470-2. PubMed ID: 1200558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and evaluation of a timolol maleate drug-resin ophthalmic suspension as a sustained-release formulation in vitro and in vivo.
    Qin F; Zeng L; Zhu Y; Cao J; Wang X; Liu W
    Drug Dev Ind Pharm; 2016; 42(4):535-45. PubMed ID: 26368660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and characterization of niosomes containing rifampicin for lung targeting.
    Jain CP; Vyas SP
    J Microencapsul; 1995; 12(4):401-7. PubMed ID: 8583314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis.
    Alvi IA; Madan J; Kaushik D; Sardana S; Pandey RS; Ali A
    Anticancer Drugs; 2011 Sep; 22(8):774-82. PubMed ID: 21799471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.
    Aggarwal D; Kaur IP
    Int J Pharm; 2005 Feb; 290(1-2):155-9. PubMed ID: 15664141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin.
    Pardakhty A; Varshosaz J; Rouholamini A
    Int J Pharm; 2007 Jan; 328(2):130-41. PubMed ID: 16997517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polysaccharide coated niosomes for oral drug delivery: formulation and in vitro stability studies.
    Sihorkar V; Vyas SP
    Pharmazie; 2000 Feb; 55(2):107-13. PubMed ID: 10723768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged release biodegradable vesicular carriers for rifampicin--formulation and kinetics of release.
    Kamath MP; Shenoy BD; Tiwari SB; Karki R; Udupa N; Kotian M
    Indian J Exp Biol; 2000 Feb; 38(2):113-8. PubMed ID: 11218826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol.
    Devaraj GN; Parakh SR; Devraj R; Apte SS; Rao BR; Rambhau D
    J Colloid Interface Sci; 2002 Jul; 251(2):360-5. PubMed ID: 16290741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride.
    Abdelbary A; Salem HF; Khallaf RA; Ali AM
    Pharm Dev Technol; 2017 May; 22(3):409-417. PubMed ID: 27476543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.
    Balakrishnan P; Shanmugam S; Lee WS; Lee WM; Kim JO; Oh DH; Kim DD; Kim JS; Yoo BK; Choi HG; Woo JS; Yong CS
    Int J Pharm; 2009 Jul; 377(1-2):1-8. PubMed ID: 19394413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.
    Emad Eldeeb A; Salah S; Ghorab M
    Drug Deliv; 2019 Dec; 26(1):509-521. PubMed ID: 31090464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops.
    Normann EK; Bakken O; Peltola J; Andréasson B; Buhl S; Sigg P; Nielsen K
    Acta Ophthalmol Scand; 2002 Apr; 80(2):183-7. PubMed ID: 11952486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection.
    Sohrabi S; Haeri A; Mahboubi A; Mortazavi A; Dadashzadeh S
    Int J Biol Macromol; 2016 Apr; 85():625-33. PubMed ID: 26794314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entrapment enhancement of peptide drugs in niosomes.
    Manosroi A; Khanrin P; Werner RG; Götz F; Manosroi W; Manosroi J
    J Microencapsul; 2010 May; 27(3):272-80. PubMed ID: 20113169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vancomycin-loaded niosomes integrated within pH-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation.
    Allam A; El-Mokhtar MA; Elsabahy M
    J Pharm Pharmacol; 2019 Aug; 71(8):1209-1221. PubMed ID: 31124593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization.
    Abdelkader H; Ismail S; Kamal A; Alany RG
    Pharmazie; 2010 Nov; 65(11):811-7. PubMed ID: 21155387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies.
    Hathout RM; Mansour S; Mortada ND; Guinedi AS
    AAPS PharmSciTech; 2007 Jan; 8(1):1. PubMed ID: 17408209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mannosylated niosomes as carrier adjuvant system for topical immunization.
    Jain S; Vyas SP
    J Pharm Pharmacol; 2005 Sep; 57(9):1177-84. PubMed ID: 16105238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.
    Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
    J Drug Target; 2011 Jul; 19(6):409-17. PubMed ID: 20678034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.